FDA Approves Production of PET Agent for Prostate Cancer
The FDA has approved the production and use of PET imaging agent Choline C 11 injection for identifying recurrent prostate cancer.
The FDA has approved the production and use of PET imaging agent Choline C 11 injection for identifying recurrent prostate cancer.
The Mayo Clinic in Rochester, Minn., was cleared as the first facility to manufacture Choline C 11 injections, the agency announced.
Choline C 11 has been used for several years, but the new approval procedures and good manufacturing practice requirements under the FDA Modernization Act opened the door for specialized facilities to produce the imaging agent.
PET imaging with Choline C 11 is used in patients who have rising levels of blood prostate specific antigen (PSA), the protein produced by the prostate gland. Elevated PSA levels can indicate a cancer recurrence even when traditional imaging studies, such as CT scans, show no signs of the disease. Choline C 11 injections help pinpoint the site of prostate cancers in recurrent cases when these other imaging tests come back negative.
Mayo Clinic researchers published a study on the efficacy of Choline C 11 injections in patients with recurrent prostate cancer in 2011 in the Journal of Nuclear Medicine. This research determined Choline C 11 use enhances prostate cancer lesion detection by roughly 30 percent.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
